Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SLDB vs ARVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SLDB Captures Overall Composite Edge (36.5 SELL vs 52.9 HOLD), While ARVN Leads 4–1 on Growth & Valuation Pillars
SLDB Overall Winner
6-Pillar Tally: SLDB 1 – 4 ARVN (1 Tie)
Matrix Metrics: SLDB 4 – 6 ARVN
As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. SLDB trades at $6.57 (N/M Forward P/E, 0.0% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin).
- Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY).
- Technical & Structure Timing Caution: SLDB is currently in a Breakdown options structure phase (RSI 47.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SLDB vs ARVN
SLDB
Head-to-Head Winner
Solid Biosciences Inc. Common Stock
$6.57
-4.02% 1D
Market Cap
$781.3M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.14β · 76% Vol
Unified Composite Score
36.5
SELL
Tech 15.0
Fund 36.0
Flow 70.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
ARVN
Arvinas, Inc
$6.74
-1.17% 1D
Market Cap
$449.9M
TTM Revenue
$275M
Forward P/E
17.9x
Beta / 30D Vol
1.40β · 66% Vol
Unified Composite Score
52.9
HOLD
Tech 54.0
Fund 59.0
Flow 71.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SLDB 1 – 4 ARVN)
1. Valuation Multiples
ARVN
Forward P/E
N/M
17.9x
Trailing P/E
N/M
17.9x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
1.3x
2. Growth & Scale
ARVN
Revenue Growth (YoY)
-100.0%
-98.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$275M
Market Cap
$781.3M
$449.9M
3. Profitability & Quality
SLDB
Gross Margin
N/A
96.7%
Operating Margin
0.0%
-10.1%
Net Profit Margin
0.0%
-3.5%
Return on Equity (ROE)
-76.9%
-1.8%
4. Balance Sheet & Cash Flow
ARVN
Cash Generation (TTM)
-$200M
-$160M
Cash Flow Margin
N/A
-58.0%
Net Cash / Leverage
$106M Net Cash
$81M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ARVN
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
103.7% (15th %ile)
108.7% (25th %ile)
Put/Call OI Skew
0.08x (Call-Skewed)
0.01x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SLDB (4) vs ARVN (6)| Institutional Metric | SLDB | ARVN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $781.3M | $449.9M | SLDB | |
| Trailing P/E Ratio | N/M | 17.9x | ARVN | |
| Forward P/E Ratio | N/M | 17.9x | ARVN | |
| Revenue Growth (YoY) | -100.0% | -98.8% | ARVN | |
| Operating Margin (TTM) | 0.0% | -10.1% | SLDB | |
| Net Profit Margin | 0.0% | -3.5% | SLDB | |
| Return on Equity (ROE) | -76.9% | -1.8% | ARVN | |
| 52-Week Range Position | 33% ($4–$11) | 5% ($6–$15) | SLDB | |
| Beta / 30D Volatility | 2.14β · 76% Vol | 1.40β · 66% Vol | ARVN | |
| Unified Institutional Score | 36.5 / 100 (SELL) | 52.9 / 100 (HOLD) | ARVN | |
| Trailing 12M Revenue (USD) | N/A | $275M | Scale | |
| Gross Profit Margin (TTM) | N/A | 96.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 1.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$200M ($106M Net Cash) | -$160M ($81M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SLDB +22.02 pp
3M Horizon
ARVN +0.49 pp
6M Horizon
SLDB +24.07 pp
1Y Horizon
SLDB +86.07 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SLDB Revenue | ARVN Revenue | SLDB Op. Margin | ARVN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -306.3% | ARVN |
| FY2019 | N/A | $20M | N/A | -281.4% | ARVN |
| FY2020 | N/A | $20M | N/A | -554.1% | ARVN |
| FY2021 | $10M | $50M | -530.5% | -403.4% | ARVN |
| FY2022 | $10M | $130M | -1315.2% | -200.3% | ARVN |
| FY2023 | N/A | $80M | N/A | -511.5% | ARVN |
| FY2024 | N/A | $260M | N/A | -95.0% | ARVN |
| FY2025 | N/A | $260M | N/A | -45.1% | ARVN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SLDB
BREAKDOWN
Current IV
103.7%
IV Percentile
15th %ile
Put/Call OI Skew
0.08x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact SLDB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ARVN
BREAKDOWN
Current IV
108.7%
IV Percentile
25th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SLDB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ARVN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SLDB vs ARVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. SLDB trades at $6.57 (N/M Forward P/E, 0.0% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY). Technical & Structure Timing Caution: SLDB is currently in a Breakdown options structure phase (RSI 47.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARVN leads the Growth & Scale pillar: SLDB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SLDB cumulative revenue shifted +0.0% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, SLDB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.
ARVN screens cheaper on headline valuation multiples. SLDB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLDB (-76.9% ROE) versus ARVN (-1.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SLDB carries 103.7% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 76% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ARVN vs SLDB · Reverse Pair
SLDB vs RGNX
· Sector Peer
SLDB vs MGTX
· Sector Peer
SLDB vs STOK
· Sector Peer
ARVN vs KYMR
· Sector Peer
ARVN vs DNLI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem